<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Ebetrex; Methotrexate: rheumatic disease" /><meta name="IX" content="Ebetrex; Methotrexate: rheumatic disease" /><title>Ebetrex®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="215543.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="215543.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=215543.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2077.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="5182.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="5288.htm">10.1.3 Drugs that suppress the rheumatic disease process</a> &gt; <a href="5304.htm">Drugs affecting the immune response</a> &gt; <a href="5305.htm">METHOTREXATE</a> &gt; <a href="130052.htm">Parenteral preparations</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="82653.htm" title="Previous: LEFLUNOMIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="202659.htm" title="Next: Cytokine modulators">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a382018.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Methotrexate, Methotrexate Sodium</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/9550-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Methotrexate</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: M &gt; Interactions of Methotrexate</p></div></li></ul><ul><li><h3>British National Formulary (12)</h3></li><li><a href="100022.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Inflammatory bowel disease</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders</p></div></li><li><a href="201304.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">METHOTREXATE</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response</p></div></li><li><a href="4725.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">8.1.3 Antimetabolites</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22methotrexate%22%22methotrexate%22%22methotrexate%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (12)</a></li></ul><ul><li><h3>BNF for Children (14)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/100022.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Inflammatory bowel disease</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/201978.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">1.5.3 Drugs affecting the immune response</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/200657.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">METHOTREXATE</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22methotrexate%22%22methotrexate%22%22methotrexate%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (14)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK-TD-c504-mn0004.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Maitotoxin</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; M</p></div></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1047.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Methotrexate</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; M</p></div></li></ul><ul><li><h3>Dietary Supplements</h3></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c39.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Folic acid</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; F</p></div></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a582123.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Methotrexate Sodium</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; M</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0012s0181.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Methotrexate</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; M</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/ms-9550-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Methotrexate</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/05985.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Methotrexate</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; M &gt; ME</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E2E3E0R0D72.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Methotrexate</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; M</p></div></li></ul><ul><li><h3>Drug Administration via Enteral Feeding Tubes</h3></li><li><a href="http://www.medicinescomplete.com/mc/tubes/2010/c240.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Methotrexate</a><div class="breadcrumb"><p><strong>Drug Administration via Enteral Feeding Tubes</strong> &gt; Handbook of Drug Administration via Enteral Feeding Tubes &gt; Monographs &gt; M</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_5305">METHOTREXATE</h1><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i511.htm" title="Go to appendix 1">Methotrexate</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">see under dose; Crohn’s disease [unlicensed
indication] (<a title="BNF:monograph: METHOTREXATE" href="201304.htm#_201304">section 1.5.3</a>); malignant disease (<a title=" Antimetabolites" href="4725.htm#_4725">section 8.1.3</a>); psoriasis (<a title="sub-section: Drugs affecting the immune response" href="106473.htm#_106473">section 13.5.3</a>)</p></div><div class="cAF" id="_5305.1"><h2>Cautions</h2> <p class="cAF"><a title="topic: Side-effects of cytotoxic drugs" href="100100.htm#_100100">section 8.1</a>; see Monitoring, Blood Count, Liver
Toxicity, and Pulmonary Toxicity below; extreme caution
in blood disorders (avoid if severe); peptic
ulceration, ulcerative colitis, diarrhoea and ulcerative
stomatitis (withdraw if stomatitis develops—may be first sign of gastro-intestinal toxicity); risk of accumulation
in pleural effusion or ascites—drain before treatment; acute porphyria (<a title=" Acute porphyrias" href="5181.htm#_5181">section 9.8.2</a>); <b>interactions:</b> see below and Appendix 1 (<span>methotrexate</span>)</p><div class="cN"><h3 class="cBP">Monitoring</h3><p>In view of reports of blood dyscrasias (including fatalities)
and liver cirrhosis with low-dose <span>methotrexate</span> patients
should:</p><ul class="cBF"><li><p class="cQ">have full blood count and renal and liver
function tests before starting treatment and repeated every 1–2 weeks
until therapy stabilised, thereafter patients should be monitored
every 2–3 months<sup class="footnote"><a title="Go to footnote" href="215543.htm#footnote215574">(1)</a></sup></p></li><li><p class="cQ">be advised to report all symptoms and signs
suggestive of infection, especially sore throat</p></li></ul><p>Treatment with folinic acid (as <span>calcium folinate</span>, <a title="BNF:monograph-family: Chemotherapy-induced mucositis and myelosuppression" href="204211.htm#_204211">section 8.1</a>) may be
required in acute toxicity</p></div><div class="cAV"><h3>Blood count</h3> <p class="cAX">Bone marrow suppression can occur
abruptly; factors likely to increase toxicity include advanced age, renal impairment, and concomitant use with another anti-folate drug (e.g. trimethoprim). A clinically significant drop in white cell
count or platelet count calls for immediate withdrawal of <span>methotrexate</span> and introduction of supportive therapy</p></div><div class="cAV"><h3>Liver toxicity</h3> <p class="cAX">Liver cirrhosis reported. Treatment
should not be started or should be discontinued if any abnormality
of liver function tests or liver biopsy is present or develops during
therapy. Abnormalities can return to normal within 2
weeks after which treatment may be recommenced if judged appropriate</p></div><div class="cAV"><h3>Pulmonary toxicity</h3> <p class="cAX">Pulmonary toxicity
may be a special problem in rheumatoid arthritis (patient to seek
medical attention if dyspnoea, cough or fever); monitor
for symptoms at each visit—discontinue if pneumonitis suspected.</p></div><div class="cAV"><h3><span>Aspirin</span> and other NSAIDs</h3> <p class="cAX">If <span>aspirin</span> or other NSAIDs are given concurrently the dose
of <span>methotrexate</span> should be carefully monitored. Patients should be advised to avoid self-medication with over-the-counter <span>aspirin</span> or <span>ibuprofen</span></p></div></div><div class="cAF" id="_5305.3"><h2>Contra-indications</h2> <p class="cAF">see Cautions above; active infection and immunodeficiency syndromes</p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">avoid—dose-related toxicity; see also Cautions above</p></div><div class="cAF"><h2>Renal impairment</h2> <p class="cAF">reduce dose; risk of nephrotoxicity at high doses; avoid
in severe impairment</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">avoid (teratogenic; fertility may be reduced during
therapy but this may be reversible); effective contraception required
during and for at least 3 months after treatment in men or women;
see also <a title="target-block: Cytotoxic drugs: Reproductive function" href="100100.htm#_100100.2">section 8.1</a></p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">discontinue breast-feeding; present in milk</p></div><div class="cAF" id="_5305.2"><h2>Side-effects</h2> <p class="cAF"><a title="topic: Side-effects of cytotoxic drugs" href="100100.htm#_100100">section 8.1</a>; also anorexia, abdominal discomfort,
dyspepsia, gastro-intestinal ulceration and bleeding, diarrhoea, toxic
megacolon, hepatotoxicity (see Cautions above); hypotension, pericarditis,
pericardial tamponade; pulmonary oedema, pleuritic pain, pulmonary
fibrosis, interstitial pneumonitis (see also Pulmonary Toxicity above);
anaphylactic reactions, urticaria; dizziness, chills, fever, drowsiness,
insomnia, malaise, headache, mood changes, neurotoxicity, confusion,
paraesthesia; precipitation of diabetes; menstrual disturbances, vaginitis,
cystitis, reduced libido, impotence; blood disorders; haematuria,
dysuria, renal failure; osteoporosis, arthralgia, myalgia, vasculitis;
conjunctivitis, visual disturbance; rash, pruritus, Stevens-Johnson
syndrome, toxic epidermal necrolysis, photosensitivity, changes in
nail and skin pigmentation, telangiectasia, acne, furuncolosis, ecchymosis;
injection-site reactions</p></div><div class="cAF"><h2>Dose</h2> <p class="cR">Moderate to severe active rheumatoid arthritis, <span class="cU">by mouth</span>, <span class="cAK">adult</span> over 18 years,
7.5 mg once weekly, adjusted according to response; max. weekly dose
20 mg</p><p class="cR">Severe active rheumatoid arthritis, <span class="cU">by subcutaneous</span> <i>or</i> <span class="cU">by intramuscular</span> <i>or</i> <span class="cU">by intravenous injection</span>, <span class="cAK">adult</span> over 18 years, 7.5 mg once weekly, increased according to response
by 2.5 mg weekly; max. weekly dose 25 mg</p><p class="cR"><span class="cAK">child</span> under 18 years see <a href="http://www.medicinescomplete.com/mc/bnfc/current/5305.htm" title="BNFC:monograph: METHOTREXATE"><i>BNF for Children</i></a></p><div class="cN"><h3 class="cBP">Important</h3><p>Note that the above dose is a <b>weekly</b> dose.
To avoid error with low-dose methotrexate, it is recommended that:</p><ul class="cBF"><li><p class="cQ">the patient is carefully advised of the <b>dose</b> and <b>frequency</b> and the reason for taking methotrexate
and any other prescribed medicine (e.g. folic acid);</p></li><li><p class="cQ">only one strength of methotrexate tablet (usually 2.5
mg) is prescribed and dispensed;</p></li><li><p class="cQ">the prescription and the dispensing label clearly show
the dose and frequency of methotrexate administration;</p></li><li><p class="cQ">the patient is warned to report immediately the onset
of any feature of blood disorders (e.g. sore throat, bruising, and
mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort,
and dark urine), and respiratory effects (e.g. shortness of breath).</p></li></ul></div><div class="cN"><h3 class="cBP">Methotrexate treatment booklets</h3><p>Methotrexate treatment
booklets should be issued where appropriate, and are available for
purchase from:</p><address>3M Security Print and Systems Limited<br />Gorse Street, Chadderton<br />Oldham<br />OL9 9QH<br /></address><div class="cBA"><div>
      Tel:
      0845 610 1112</div></div><p>GP practices can obtain supplies through their
Primary Care Trust (PCT) or Agency stores.</p><p>NHS Hospitals can order supplies from <a href="http://www.nhsforms.co.uk" title="external link">www.nhsforms.co.uk</a> or by emailing nhsforms@mmm.com.</p><p>These booklets include advice for adults taking oral methotrexate
for inflammatory conditions, and a section for recording results of
blood tests and dosage information.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="128179.htm#_128179" title="Methotrexate">Methotrexate</a></li><li><h1 class="title">Parenteral preparations</h1><p>See also <a title="preparation: Methotrexate" href="4738.htm#_4738">section 8.1.3</a></p><ul><li class="jN" id="_215543" style="margin: 0 0 0 20px;"><h1 class="title">Ebetrex®<span> (<a href="appendix-112803-S.htm#m647">Sandoz</a>)</span> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Injection</span>, prefilled syringe, methotrexate
(as disodium salt) 10 mg/mL, net price 0.75 mL (7.5 mg) = £14.78,
1 mL (10 mg) = £15.21, 1.5 mL (15 mg) = £16.49; 20 mg/mL, 1 mL (20 mg)
= £17.75, 1.25 mL (25 mg) = £18.39, 1.5 mL (30 mg) = £20.70</div></li><li><a href="129942.htm#_129942" title="Metoject®">Metoject®</a></li></ul></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="82653.htm">Previous: LEFLUNOMIDE</a> | <a class="top" href="215543.htm#">Top</a> | <a accesskey="]" href="202659.htm">Next: Cytokine modulators</a> ►</div><div class="cF"><div class="footnote" id="footnote215574"><sup>(1)</sup>Local protocols for frequency of monitoring may
vary</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>